Cover Image
市場調查報告書

止血劑:醫療設備的開發平台評估

Hemostats - Medical Devices Pipeline Assessment, 2016

出版商 GlobalData 商品編碼 356282
出版日期 內容資訊 英文 118 Pages
訂單完成後即時交付
價格
Back to Top
止血劑:醫療設備的開發平台評估 Hemostats - Medical Devices Pipeline Assessment, 2016
出版日期: 2016年03月11日 內容資訊: 英文 118 Pages
簡介

本報告提供全球止血劑市場上的主要開發中產品 (醫療設備) 及其臨床實驗的進展調查,再加上產品特性比較分析 (臨床實驗的各進展階段) ,並彙整主要企業簡介及代表性產品,近來的市場動靜 (授權合約·產業聯盟等) 資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 止血劑概要

第3章 臨床實驗中的產品

  • 開發中產品:各臨床實驗階段
  • 開發中產品:各市場區隔
  • 開發中產品:各地區
  • 開發中產品:各法規途徑
  • 開發中產品:估計各認證時期
  • 開發中產品:現在進行中的臨床實驗

第4章 臨床實驗中的開發中產品:各企業

  • 止血劑的企業:各臨床實驗階段的開發中產品
  • 止血劑:各臨床實驗階段的開發中產品

第5章 止血劑市場:企業·產品概要

  • 3-D Matrix, Ltd.
    • 開發中產品及進行中的臨床實驗概要
  • Advanced Medical Solutions Group plc
  • Anika Therapeutics, Inc.
  • Arch Therapeutics Inc.
  • Argon Medical Devices Inc.
  • Baxter International Inc.
  • Beth Israel Deaconess Medical Center, Inc.
  • Biomedica Management Corporation
  • Biom'Up SAS
  • Cellphire, Inc.
  • Covalent Medical, Inc. (Inactive)
  • Covalon Technologies Ltd.
  • CryoLife, Inc.
  • Endomedix Incorporated
  • Entegrion, Inc.
  • Ethicon, Inc.
  • Floralis S.A.S.
  • Gamma Therapeutics, Inc.
  • Haemostatix Limited
  • Hemostasis, LLC
  • KeraNetics, LLC
  • LifeBond Ltd.
  • Remedium Technologies Inc.
  • Rice University
  • Samyang Biopharmaceuticals
  • Sanofi
  • Sea Run Holdings Inc.
  • St Teresa Medical, Inc.
  • Suneris Technologies, Inc.
  • The Medicines Company
  • Therus Corporation
  • Xcede Technologies, Inc.

第6章 止血市場:目前的趨勢 (全35件)

第7章 附錄

圖表一覽

目錄
Product Code: GDME0161EPD

GlobalData's Medical Devices sector report, "Hemostats - Medical Devices Pipeline Assessment, 2016" provides an overview of Hemostats currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Hemostats pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Hemostats under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Hemostats and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Hemostats under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Hemostats Overview

3. Products under Development

  • 3.1. Hemostats - Pipeline Products by Stage of Development
  • 3.2. Hemostats - Pipeline Products by Segment
  • 3.3. Hemostats - Pipeline Products by Territory
  • 3.4. Hemostats - Pipeline Products by Regulatory Path
  • 3.5. Hemostats - Pipeline Products by Estimated Approval Date
  • 3.6. Hemostats - Ongoing Clinical Trials

4. Hemostats - Pipeline Products under Development by Companies

  • 4.1. Hemostats Companies - Pipeline Products by Stage of Development
  • 4.2. Hemostats - Pipeline Products by Stage of Development

5. Hemostats Companies and Product Overview

  • 5.1. 3-D Matrix, Ltd. Company Overview
    • 5.1.1. 3-D Matrix, Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.2. Advanced Medical Solutions Group plc Company Overview
    • 5.2.1. Advanced Medical Solutions Group plc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.3. Anika Therapeutics, Inc. Company Overview
    • 5.3.1. Anika Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.4. Arch Therapeutics Inc. Company Overview
    • 5.4.1. Arch Therapeutics Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.5. Argon Medical Devices Inc. Company Overview
    • 5.5.1. Argon Medical Devices Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.6. Baxter International Inc. Company Overview
    • 5.6.1. Baxter International Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.7. Beth Israel Deaconess Medical Center, Inc. Company Overview
    • 5.7.1. Beth Israel Deaconess Medical Center, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.8. Biomedica Management Corporation Company Overview
    • 5.8.1. Biomedica Management Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.9. Biom'Up SAS Company Overview
    • 5.9.1. Biom'Up SAS Pipeline Products & Ongoing Clinical Trials Overview
  • 5.10. Cellphire, Inc. Company Overview
    • 5.10.1. Cellphire, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.11. Covalent Medical, Inc. (Inactive) Company Overview
    • 5.11.1. Covalent Medical, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • 5.12. Covalon Technologies Ltd. Company Overview
    • 5.12.1. Covalon Technologies Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.13. CryoLife, Inc. Company Overview
    • 5.13.1. CryoLife, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.14. Endomedix Incorporated Company Overview
    • 5.14.1. Endomedix Incorporated Pipeline Products & Ongoing Clinical Trials Overview
  • 5.15. Entegrion, Inc. Company Overview
    • 5.15.1. Entegrion, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.16. Ethicon, Inc. Company Overview
    • 5.16.1. Ethicon, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.17. Floralis S.A.S. Company Overview
    • 5.17.1. Floralis S.A.S. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.18. Gamma Therapeutics, Inc. Company Overview
    • 5.18.1. Gamma Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.19. Haemostatix Limited Company Overview
    • 5.19.1. Haemostatix Limited Pipeline Products & Ongoing Clinical Trials Overview
  • 5.20. Hemostasis, LLC Company Overview
    • 5.20.1. Hemostasis, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • 5.21. KeraNetics, LLC Company Overview
    • 5.21.1. KeraNetics, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • 5.22. LifeBond Ltd. Company Overview
    • 5.22.1. LifeBond Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.23. Remedium Technologies Inc. Company Overview
    • 5.23.1. Remedium Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.24. Rice University Company Overview
    • 5.24.1. Rice University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.25. Samyang Biopharmaceuticals Corporation Company Overview
    • 5.25.1. Samyang Biopharmaceuticals Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.26. Sanofi Company Overview
    • 5.26.1. Sanofi Pipeline Products & Ongoing Clinical Trials Overview
  • 5.27. Sea Run Holdings Inc. Company Overview
    • 5.27.1. Sea Run Holdings Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.28. St Teresa Medical, Inc. Company Overview
    • 5.28.1. St Teresa Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.29. Suneris Technologies, Inc. Company Overview
    • 5.29.1. Suneris Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.30. The Medicines Company Company Overview
    • 5.30.1. The Medicines Company Pipeline Products & Ongoing Clinical Trials Overview
  • 5.31. Therus Corporation Company Overview
    • 5.31.1. Therus Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.32. Xcede Technologies, Inc. Company Overview
    • 5.32.1. Xcede Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview

6. Hemostats- Recent Developments

  • 6.1. Feb 18, 2016: Genelife Enters into Licensing Agreement with 3-D Matrix Europe
  • 6.2. Feb 17, 2016: Z-Medica Receives Expanded CE Mark for QuikClot
  • 6.3. Jan 21, 2016: United Health Products Announces Optimal Government Services as UHP's Exclusive Government Distributor
  • 6.4. Dec 16, 2015: Arch Therapeutics Receives Clearance to Initiate Clinical Trial in Europe
  • 6.5. Dec 09, 2015: Arsenal Medical Secures Funding from U.S. Army to Advance ResQFoam Trauma Product through Regulatory Approval
  • 6.6. Dec 04, 2015: Change in B. Braun Management Board
  • 6.7. Dec 01, 2015: Arch Therapeutics Reports Significant Wound Healing Results in Pre-Clinical Safety Study with AC5 Surgical Hemostatic Device
  • 6.8. Nov 17, 2015: CryoLife Announces Resolution of PerClot Litigation with Medafor
  • 6.9. Oct 28, 2015: United Health Products' HemoStyp Now Available Through Henry Schein
  • 6.10. Oct 22, 2015: CoAg Medical And Lou Ferrigno Announce StopsBleeding Product Launch
  • 6.11. Oct 20, 2015: Vascular Solutions Reports Third Quarter Results-2015
  • 6.12. Sep 08, 2015: Arch Therapeutics Obtains Additional Positive Safety Data for AC5 Surgical Hemostatic Device in Preclinical Toxicity Test of Sensitization
  • 6.13. Aug 24, 2015: United Health Products Announces School Health as a Distributor
  • 6.14. Aug 18, 2015: Dynasil Announces Xcede Technologies' Patent Application for Novel All-in-One Patch
  • 6.15. Aug 05, 2015: LifeBond Raises USD27 Million in Series D Financing
  • 6.16. Aug 04, 2015: Suneris CEO to Present VETIGEL at White House Demo Day
  • 6.17. Jul 21, 2015: Vascular Solutions Reports Second Quarter Results
  • 6.18. Jul 15, 2015: Remedium Technologies Receives FDA Clearance for Hemogrip Technology to Help Stop Bleeding
  • 6.19. Jul 14, 2015: St. Teresa Medical Announces First Patient Enrolled in SURGICLOT Clinical Trial in U.K
  • 6.20. Jun 26, 2015: Suneris Introduces VETIGEL as a New Wound Care Solution for Veterinarians
  • 6.21. Jun 15, 2015: OxySure Systems Enters into Distribution Agreement with Z-Medica
  • 6.22. Jun 09, 2015: Arch Therapeutics Obtains Additional Safety Data for Its AC5 Surgical Hemostatic Device in Successful Preclinical Toxicity Test
  • 6.23. May 13, 2015: DuBiotech Welcomes Germany's B.Braun
  • 6.24. Apr 30, 2015: The Medicines Company Announces FDA Approval of RAPLIXA (Fibrin Sealant), the First and Only Powdered Fibrin Sealant Ready-to-Use for Mild to Moderate Surgical Bleeding
  • 6.25. Apr 28, 2015: CryoLife Begins Patient Enrolment In PerClot IDE Clinical Trial
  • 6.26. Apr 21, 2015: Vascular Solutions Reports First Quarter Results
  • 6.27. Apr 16, 2015: Arch Therapeutics' AC5 Compared Favorably vs. Commercially Available Combination Hemostat in Animal Study
  • 6.28. Apr 14, 2015: Arch Therapeutics Announces Favorable Preclinical Data From an Independent Study of AC5 Surgical Hemostatic Device Versus a Popular Fibrin Sealant
  • 6.29. Apr 07, 2015: United Health Products Announces Laboratory Test Results
  • 6.30. Apr 01, 2015: Z-Medica Announces QuikClot Products Approved in California
  • 6.31. Mar 27, 2015: B. Braun Group increases sales and earnings
  • 6.32. Mar 25, 2015: Arch Therapeutics Announces Favorable Preclinical Data from an Independent Study of AC5 Surgical Hemostatic Device Versus a Popular Cellulose-Based Hemostatic Agent
  • 6.33. Mar 23, 2015: Arch Therapeutics Announces Positive Safety Results for AC5 Surgical Hemostatic Device in Preclinical Toxicity Studies
  • 6.34. Mar 13, 2015: Withdrawal of Application for the Approval of the Hemostat (TDM-621)
  • 6.35. Mar 12, 2015: CryoLife Provides Update on PerClot Litigation

7. Appendix

  • 7.1. Methodology
  • 7.2. About GlobalData
  • 7.3. Contact Us
  • 7.4. Disclaimer

List of Tables

  • Table 1: Hemostats - Pipeline Products by Stage of Development
  • Table 2: Hemostats - Pipeline Products by Segment
  • Table 3: Hemostats - Pipeline Products by Territory
  • Table 4: Hemostats - Pipeline Products by Regulatory Path
  • Table 5: Hemostats - Pipeline Products by Estimated Approval Date
  • Table 6: Hemostats - Ongoing Clinical Trials
  • Table 7: Hemostats Companies - Pipeline Products by Stage of Development
  • Table 8: Hemostats - Pipeline Products by Stage of Development
  • Table 9: 3-D Matrix, Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 10: PuraStat Hemostat - Product Status
  • Table 11: PuraStat Hemostat - Product Description
  • Table 12: TDM-511 - Product Status
  • Table 13: TDM-511 - Product Description
  • Table 14: Advanced Medical Solutions Group plc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 15: Antibiotic Hemostat - Product Status
  • Table 16: Antibiotic Hemostat - Product Description
  • Table 17: GENTA-COLL Resorb - Product Status
  • Table 18: GENTA-COLL Resorb - Product Description
  • Table 19: GENTA-FOIL Resorb - Product Status
  • Table 20: GENTA-FOIL Resorb - Product Description
  • Table 21: KOLLAGEN resorb - Product Status
  • Table 22: KOLLAGEN resorb - Product Description
  • Table 23: RESORBA CELL Fibrillar - Product Status
  • Table 24: RESORBA CELL Fibrillar - Product Description
  • Table 25: RESORBA CELL forte - Product Status
  • Table 26: RESORBA CELL forte - Product Description
  • Table 27: RESORBA CELL standard - Product Status
  • Table 28: RESORBA CELL standard - Product Description
  • Table 29: Anika Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 30: Hemostatic Patch - Product Status
  • Table 31: Hemostatic Patch - Product Description
  • Table 32: Arch Therapeutics Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 33: AC5 Surgical Hemostatic Device - Product Status
  • Table 34: AC5 Surgical Hemostatic Device - Product Description
  • Table 35: Arch Therapeutics Inc. - Ongoing Clinical Trials Overview
  • Table 36: AC5 Surgical Hemostatic Device - AC5 Surgical Hemostatic Device Clinical Trial in Europe
  • Table 37: Argon Medical Devices Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 38: Hemaseel Thrombin Haemostatic Agent - Product Status
  • Table 39: Hemaseel Thrombin Haemostatic Agent - Product Description
  • Table 40: Baxter International Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 41: Hemopatch - Product Status
  • Table 42: Hemopatch - Product Description
  • Table 43: Baxter International Inc. - Ongoing Clinical Trials Overview
  • Table 44: Hemopatch - A Phase II Prospective, Single Blinded, Randomized Trial of Hemopatch Compared to Standard Techniques to Achieve Air Leak Control After Complex Thoracic Surgical Procedures on High Risk Population for Prolonged Air Leak (> 5 Days - PAL)
  • Table 45: Hemopatch - A Prospective Randomized Trial of Hemopatch Versus No Hemopatch for the Intraoperative Hemostasis During Deceased Donor Renal Transplant
  • Table 46: Hemopatch - Prospective Randomized Clinical Trial to Prevent Air Leaks After Lung Resection with Hemopatch Sealing Hemostat: SEALLS (Sealing Evaluation of Air Leaks After Lung Surgery) Trial
  • Table 47: Hemopatch - Prospective, Multicenter, Open-label, Randomized, Phase III Clinical Trial of Prevention of Prolonged Air Leak after Lung Resection in High-risk Patients, Applying HEMOPATCH
  • Table 48: Beth Israel Deaconess Medical Center, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 49: Portable Wound Hemostasis System - Product Status
  • Table 50: Portable Wound Hemostasis System - Product Description
  • Table 51: Biomedica Management Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 52: ClotFoam - Product Status
  • Table 53: ClotFoam - Product Description
  • Table 54: ClotGel - Product Status
  • Table 55: ClotGel - Product Description
  • Table 56: ClotSpray - Product Status
  • Table 57: ClotSpray - Product Description
  • Table 58: Biom'Up SAS Pipeline Products & Ongoing Clinical Trials Overview
  • Table 59: Hemoblast Bellows - Product Status
  • Table 60: Hemoblast Bellows - Product Description
  • Table 61: Cellphire, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 62: Thromboderm - Product Status
  • Table 63: Thromboderm - Product Description
  • Table 64: Thrombosomes - Hemostatic Agent - Product Status
  • Table 65: Thrombosomes - Hemostatic Agent - Product Description
  • Table 66: Covalent Medical, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • Table 67: CovaSTAT - Product Status
  • Table 68: CovaSTAT - Product Description
  • Table 69: Covalon Technologies Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 70: ColActive THP - Product Status
  • Table 71: ColActive THP - Product Description
  • Table 72: CovaStat BioActive Absorbable Hemostatic Sponge - Product Status
  • Table 73: CovaStat BioActive Absorbable Hemostatic Sponge - Product Description
  • Table 74: CryoLife, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 75: PerClot - Product Status
  • Table 76: PerClot - Product Description
  • Table 77: CryoLife, Inc. - Ongoing Clinical Trials Overview
  • Table 78: PerClot - Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot Polysaccharide Hemostatic System
  • Table 79: Endomedix Incorporated Pipeline Products & Ongoing Clinical Trials Overview
  • Table 80: Internal Hemostat - Product Status
  • Table 81: Internal Hemostat - Product Description
  • Table 82: Topical Hemostat - Product Status
  • Table 83: Topical Hemostat - Product Description
  • Table 84: Entegrion, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 85: Stasix - Product Status
  • Table 86: Stasix - Product Description
  • Table 87: Ethicon, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 88: Flowable thrombin - Product Status
  • Table 89: Flowable thrombin - Product Description
  • Table 90: Floralis S.A.S. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 91: Bleeding Controlling Device - Product Status
  • Table 92: Bleeding Controlling Device - Product Description
  • Table 93: Gamma Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 94: GammaTF - Product Status
  • Table 95: GammaTF - Product Description
  • Table 96: Haemostatix Limited Pipeline Products & Ongoing Clinical Trials Overview
  • Table 97: HaemoPlax - Product Status
  • Table 98: HaemoPlax - Product Description
  • Table 99: PeproStat - Product Status
  • Table 100: PeproStat - Product Description
  • Table 101: Hemostasis, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 102: ENT Hemostat - Product Status
  • Table 103: ENT Hemostat - Product Description
  • Table 104: Hemostatic Gel - Product Status
  • Table 105: Hemostatic Gel - Product Description
  • Table 106: KeraNetics, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 107: Keratin-Based Hemostat - Product Status
  • Table 108: Keratin-Based Hemostat - Product Description
  • Table 109: LifeBond Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 110: Absorbable Hemostat - Product Status
  • Table 111: Absorbable Hemostat - Product Description
  • Table 112: LifePatch Heavy - Product Status
  • Table 113: LifePatch Heavy - Product Description
  • Table 114: LifePatch Surgery - Product Status
  • Table 115: LifePatch Surgery - Product Description
  • Table 116: Remedium Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 117: Hemogrip Spray-On Foam - Product Status
  • Table 118: Hemogrip Spray-On Foam - Product Description
  • Table 119: Rice University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 120: KOD Hydrogel Hemostat - Product Status
  • Table 121: KOD Hydrogel Hemostat - Product Description
  • Table 122: Samyang Biopharmaceuticals Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 123: B6100 - Product Status
  • Table 124: B6100 - Product Description
  • Table 125: B6102 Hemostatic ORC - Product Status
  • Table 126: B6102 Hemostatic ORC - Product Description
  • Table 127: Sanofi Pipeline Products & Ongoing Clinical Trials Overview
  • Table 128: Lumagel - Product Status
  • Table 129: Lumagel - Product Description
  • Table 130: Sea Run Holdings Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 131: SEA-STAT - Product Status
  • Table 132: SEA-STAT - Product Description
  • Table 133: St Teresa Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 134: SURGICLOT - Product Status
  • Table 135: SURGICLOT - Product Description
  • Table 136: WRAPCLOT - Product Status
  • Table 137: WRAPCLOT - Product Description
  • Table 138: St Teresa Medical, Inc. - Ongoing Clinical Trials Overview
  • Table 139: SURGICLOT - A Multicenter Study to Assess the Safety and Performance of SurgiClot in the Treatment of Cancellous Bone Bleeding
  • Table 140: Suneris Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 141: VETIGEL - Product Status
  • Table 142: VETIGEL - Product Description
  • Table 143: The Medicines Company Pipeline Products & Ongoing Clinical Trials Overview
  • Table 144: Fibropad Patch - Product Status
  • Table 145: Fibropad Patch - Product Description
  • Table 146: Therus Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 147: Therus Acoustic Hemostasis System - Product Status
  • Table 148: Therus Acoustic Hemostasis System - Product Description
  • Table 149: Xcede Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 150: Xcede Patch - Product Status
  • Table 151: Xcede Patch - Product Description
  • Table 152: Glossary

List of Figures

  • Figure 1: Hemostats - Pipeline Products by Stage of Development
  • Figure 2: Hemostats - Pipeline Products by Segment
  • Figure 3: Hemostats - Pipeline Products by Territory
  • Figure 4: Hemostats - Pipeline Products by Regulatory Path
  • Figure 5: Hemostats - Pipeline Products by Estimated Approval Date
  • Figure 6: Hemostats - Ongoing Clinical Trials
Back to Top